JelloX Research Collaborations Further Demonstrate Promise of 3D Pathology

Japan - Japanese

APAC - English

News provided by

Mar 27, 2025, 22:19 ET

Results of a Taiwan-based study are expected to be validated in a new collaboration with a major Japanese medical institution, assessing the higher sensitivity of 3D pathology over conventional sampling techniques across populations and medical systems.

HSINCHU, March 27, 2025 /PRNewswire/ -- JelloX Biotech Inc., a Taiwan-based startup at the forefront of anatomic pathology, today announced the results of a recent clinical trial conducted in collaboration with Taipei Medical University Hospital (TMUH). Focusing on the diagnosis and treatment of colorectal cancer, the study applied JelloX's 3D pathology methods to colonoscopy specimens evaluated by conventional 2D methods and identified a significant difference in pathological diagnosis, mostly from reclassifying cases into higher risk categories.

Traditional histopathology is limited to two-dimensional observations. Through 3D fluorescent pathology imaging, three-dimensional tubular structures can be clearly visualized, aiding in disease staging and diagnosis.

According to the US National Cancer Institute, colorectal cancer is one of the most common types of cancers. However, diagnosis by biopsy, though widely regarded as the most accurate method over non-invasive techniques, continues to pose precision challenges, such as the potential for improper sampling and examination.

Dr. Yen-Yin Lin, CEO of JelloX, remarked: "Backed by growing empirical data, the case ca for implementing 3D pathology in oncology is building. The 3D technology's greater sensitivity enables a higher level of precision that can help match the right patients to the right drugs at the right time—ultimately improving treatment and quality of life."

New findings in collaboration with TMUH

The clinical trial evaluated approximately 160 cases, comparing diagnoses made by traditional 2D pathology with those made using JelloX's 3D pathology on the same colon polyps samples. The findings demonstrated a high inconsistency rate between the two methods. Notably, many of these discrepancies involved cases initially classified as lower-risk by conventional methods but subsequently reclassified to higher-risk categories with 3D analysis. The results suggest that conventional methods may underestimate the malignancy transformation potential of colon polyps due to the limited information derived from the 2D images of a tissue sample.

The precision of JelloX's 3D pathology technology shows promise for bringing patients improved treatment and better quality of care. This is particularly important for colorectal cancer, since its asymptomatic nature in the early stages often results in late-stage disease, and early detection greatly improves cure rate.

JelloX, TMUH, and Taipei Li-jen Pathology Clinic are partnering to make this innovative technology available in major health check-up centers across Taiwan.

Fostering international partnerships in Japan and the US

In Japan, JelloX's 3D pathology technology is driving advancements in drug discovery, biomarker research, and precision medicine. The company is collaborating with the National Cancer Center Japan [Exploratory Oncology Research and Clinical Trial Center (EPOC) / National Cancer Center Hospital East] to conduct a study on Japanese colorectal and esophageal cancer patients. Once completed, this study may also show greater sensitivity of the 3D pathology method in a different population and medical system.

This collaboration will focus on 3D analysis of the tumor microenvironment in esophageal cancer patients undergoing neoadjuvant chemotherapy (NAC), promising insights into drug development and predictive modeling of chemotherapy efficacy. As it ramps up plans to apply for regulatory approval in Japan, JelloX also plans to establish a central laboratory in Tokyo as a regional service hub for sample processing and diagnostics.

In the US, JelloX launched a partnership in 2024 with a major research institution and is making arrangements to establish a central laboratory in Arizona, laying the groundwork for future commercial deployment.

For more information or to explore partnerships, please contact JelloX at [email protected].

About JelloX Biotech Inc.

Based in Hsinchu, Taiwan, JelloX Biotech Inc. is a startup that focuses on advancing cancer pathology through 3D digital imaging and AI technology.

For more information, please visit: https://jellox.com/en/home/

SOURCE JelloX Biotech Inc.